European Medicine Agency (EMA)
The European Medicine Agency (EMA) has established ‘eligibility criteria’ in order to make sure that it only establishes dialogues with the most suitable organisations that act in the interests of European patients, consumers and healthcare professionals. The European Association of Urology would like to engage in dialogue with the EMA and has provided the following information for the evaluation of eligibility.
Annual Financial Assessment
As part of the evaluation for eligibility, the European Association of Urology has provided the following financial information (2025) to be assessed by the parameters as set by the European Medicine Agency:
Income from non-industry:
- Registration fees - 39.7%
- Publications - 7.5%
- Membership fees - 11.1%
- Other income - 0.1%
The overall proportion of industry and non-industry:
42% vs 58%
Funding Resources
The following pharmaceutical companies provide funding to EAU:
- Astellas Pharma Europe Ltd
- Janssen Pharmaceutical N.V.
- Novartis Pharmaceuticals USA
- AstraZeneca UK Ltd.
- Pfizer Inc.
- Bayer Healthcare Pharmaceuticals, Inc.
- Merck Sharp & Dohme LLC
- Accord Healthcare France
- Medac GmbH
The following medtech companies provide funding to EAU:
- Boston Scientific International S.A.
- Olympus Europa SE & CO. KG
- Intuitive Surgical Sarl
- Covidien AG
- Coloplast Manufacturing France
- Karl Storz SE & Co. KG
- Quanta System SPA
- Procept Biorobotics
- Cook Medical Europe Ltd.
The highest contribution from a single company is less than 3.14% of the organisation’s total income. The financial Annual Report of 2025 by EAU can be found here: Compilation Report 2025.

Code of Ethics
In order to ensure good governance, interactions should be based on fundamental principles of integrity, mutual respect, responsiveness, accountability, collaboration and transparency. The EAU Code of Ethics set standards for industry partners with regard to ethical interactions with the healthcare community. In order to make funding partnerships work in practice, to ensure the integrity of both the funder and EAU is maintained, and to demonstrate to other stakeholders that our relationships are absolutely scrupulous, the following key principles underpin our acceptance of funding.